T. Rowe Price Associates
AXSM icon

T. Rowe Price Associates’s Axsome Therapeutics AXSM Stock Holding History

T. Rowe Price Associates’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223M Sell
1,317,059
-192,811
-13% -$33.3M 0.03% 435
2025
Q4 		$276M Buy
1,509,870
+472,422
+46% +$66M 0.03% 370
2025
Q3 		$126M Buy
1,037,448
+424,705
+69% +$47.8M 0.01% 570
2025
Q2 		$64M Buy
612,743
+580,766
+1,816% +$61.5M 0.01% 667
2025
Q1 		$3.73M Buy
31,977
+749
+2% +$85.3K ﹤0.01% 1347
2024
Q4 		$2.64M Buy
31,228
+3,366
+12% +$310K ﹤0.01% 1520
2024
Q3 		$2.5M Buy
27,862
+687
+3% +$60K ﹤0.01% 1541
2024
Q2 		$2.19M Buy
27,175
+1,901
+8% +$141K ﹤0.01% 1514
2024
Q1 		$2.02M Sell
25,274
-121,283
-83% -$10.2M ﹤0.01% 1557
2023
Q4 		$11.7M Buy
146,557
+123,949
+548% +$8.29M ﹤0.01% 1065
2023
Q3 		$1.58M Buy
22,608
+2,132
+10% +$159K ﹤0.01% 1570
2023
Q2 		$1.47M Buy
20,476
+4,227
+26% +$312K ﹤0.01% 1607
2023
Q1 		$1M Buy
16,249
+1,770
+12% +$116K ﹤0.01% 1785
2022
Q4 		$1.12M Buy
14,479
+380
+3% +$22.7K ﹤0.01% 1717
2022
Q3 		$630K Sell
14,099
-528
-4% -$26.4K ﹤0.01% 2005
2022
Q2 		$560K Buy
14,627
+245
+2% +$7.75K ﹤0.01% 2176
2022
Q1 		$595K Buy
14,382
+4,068
+39% +$126K ﹤0.01% 2263
2021
Q4 		$390K Sell
10,314
-9,796
-49% -$360K ﹤0.01% 2500
2021
Q3 		$663K Sell
20,110
-728,137
-97% -$28.4M ﹤0.01% 2239
2021
Q2 		$50.5M Buy
748,247
+120,909
+19% +$7.26M ﹤0.01% 1025
2021
Q1 		$35.5M Sell
627,338
-411,917
-40% -$29M ﹤0.01% 1126
2020
Q4 		$84.7M Sell
1,039,255
-9,730
-0.9% -$728K 0.01% 788
2020
Q3 		$74.7M Sell
1,048,985
-35,886
-3% -$2.8M 0.01% 742
2020
Q2 		$89.3M Buy
1,084,871
+339,511
+46% +$26.1M 0.01% 666
2020
Q1 		$43.9M Sell
745,360
-861,631
-54% -$70.2M 0.01% 826
2019
Q4 		$166M Buy
1,606,991
+898,120
+127% +$36.3M 0.02% 518
2019
Q3 		$14.3M Buy
708,871
+130,012
+22% +$3.34M ﹤0.01% 1235
2019
Q2 		$14.9M Buy
+578,859
New +$11.6M ﹤0.01% 1258

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

T. Rowe Price Associates's AXSM Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Axsome Therapeutics (AXSM) stake by 13% in Q1 2026, selling an estimated $33.3M and leaving 1,317,059 shares worth $223M. The position accounts for 0.03% of the portfolio, ranked #435.

T. Rowe Price Associates first reported a position in AXSM in Q2 2019 and has held it in 28 quarters since. The position peaked at $276M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • T. Rowe Price Associates held 1,317,059 shares of Axsome Therapeutics worth $223M as of Q1 2026.
  • T. Rowe Price Associates sold 192,811 Axsome Therapeutics shares in Q1 2026, an estimated $33.3M.
  • Axsome Therapeutics made up 0.03% of T. Rowe Price Associates's portfolio in Q1 2026, its #435 holding.
  • T. Rowe Price Associates first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • T. Rowe Price Associates's Axsome Therapeutics position peaked at $276M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.